JP2021525749A5 - - Google Patents

Info

Publication number
JP2021525749A5
JP2021525749A5 JP2020566789A JP2020566789A JP2021525749A5 JP 2021525749 A5 JP2021525749 A5 JP 2021525749A5 JP 2020566789 A JP2020566789 A JP 2020566789A JP 2020566789 A JP2020566789 A JP 2020566789A JP 2021525749 A5 JP2021525749 A5 JP 2021525749A5
Authority
JP
Japan
Prior art keywords
seq
rharg
abd
arginine
abd094
Prior art date
Application number
JP2020566789A
Other languages
English (en)
Japanese (ja)
Other versions
JP7576262B2 (ja
JPWO2019228510A5 (https=
JP2021525749A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/089583 external-priority patent/WO2019228510A1/en
Publication of JP2021525749A publication Critical patent/JP2021525749A/ja
Publication of JPWO2019228510A5 publication Critical patent/JPWO2019228510A5/ja
Publication of JP2021525749A5 publication Critical patent/JP2021525749A5/ja
Priority to JP2024091527A priority Critical patent/JP2024116237A/ja
Application granted granted Critical
Publication of JP7576262B2 publication Critical patent/JP7576262B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566789A 2018-05-31 2019-05-31 癌、肥満、代謝障害及び関連する合併症と併存症のためのアルギニン枯渇剤の組成と応用 Active JP7576262B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024091527A JP2024116237A (ja) 2018-05-31 2024-06-05 癌、肥満、代謝障害及び関連する合併症と併存症のためのアルギニン枯渇剤の組成と応用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862678300P 2018-05-31 2018-05-31
US62/678,300 2018-05-31
PCT/CN2019/089583 WO2019228510A1 (en) 2018-05-31 2019-05-31 Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024091527A Division JP2024116237A (ja) 2018-05-31 2024-06-05 癌、肥満、代謝障害及び関連する合併症と併存症のためのアルギニン枯渇剤の組成と応用

Publications (4)

Publication Number Publication Date
JP2021525749A JP2021525749A (ja) 2021-09-27
JPWO2019228510A5 JPWO2019228510A5 (https=) 2022-07-19
JP2021525749A5 true JP2021525749A5 (https=) 2022-07-19
JP7576262B2 JP7576262B2 (ja) 2024-10-31

Family

ID=68697862

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566789A Active JP7576262B2 (ja) 2018-05-31 2019-05-31 癌、肥満、代謝障害及び関連する合併症と併存症のためのアルギニン枯渇剤の組成と応用
JP2024091527A Pending JP2024116237A (ja) 2018-05-31 2024-06-05 癌、肥満、代謝障害及び関連する合併症と併存症のためのアルギニン枯渇剤の組成と応用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024091527A Pending JP2024116237A (ja) 2018-05-31 2024-06-05 癌、肥満、代謝障害及び関連する合併症と併存症のためのアルギニン枯渇剤の組成と応用

Country Status (13)

Country Link
US (1) US20200181597A1 (https=)
EP (2) EP4616911A3 (https=)
JP (2) JP7576262B2 (https=)
KR (1) KR20210016434A (https=)
CN (2) CN116920081A (https=)
AU (2) AU2019275733B2 (https=)
BR (1) BR112020024227A2 (https=)
CA (1) CA3101667A1 (https=)
ES (1) ES3049232T3 (https=)
IL (2) IL278993B2 (https=)
SG (1) SG11202011838XA (https=)
TW (2) TWI868683B (https=)
WO (1) WO2019228510A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020009740A2 (en) * 2018-04-25 2020-01-09 Washington University Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
EP4616911A3 (en) * 2018-05-31 2025-12-24 The Chinese University of Hong Kong Arginase albumin binding domain fusion proteins and methods of use thereof
WO2020018732A1 (en) * 2018-07-19 2020-01-23 Ab Studio Inc. Novel systems for screening internalizing antibody and uses thereof
CA3116736A1 (en) 2018-10-19 2020-04-23 Aerase, Inc. Arginine depletion therapy for treatment of gamt deficiency
CN114729344A (zh) 2019-08-30 2022-07-08 安格利亚生物制药公司 人重组精氨酸酶1的生产方法及其用途
CN115038460A (zh) * 2019-12-02 2022-09-09 香港理工大学 诱导间歇性禁食和调节自噬的方法
WO2021126184A1 (en) * 2019-12-18 2021-06-24 Hill's Pet Nutrition, Inc. Methods for identifying a companion animal at risk of calcium oxalate stone formation and treatments and compositions for reducing the risk
CA3180529A1 (en) * 2020-04-17 2021-10-21 Bio-Cancer Treatment International Limited Methods of treating viral infections using arginase
WO2021257523A1 (en) * 2020-06-15 2021-12-23 Aeglea Biotherapeutics, Inc. Use of arginase for treatment of influenza infections
WO2022195629A1 (en) * 2021-03-18 2022-09-22 National Institute Of Pharmaceutical Education And Research (Niper) Engineered arginase constructs, method of generation and uses thereof
EP4405384A1 (en) * 2021-09-20 2024-07-31 Kyon Biotech AG Arginase-insulin fusion protein
CN120383669B (zh) * 2025-04-24 2025-10-28 广东医科大学 一种重组人长效白细胞介素-22结合蛋白的制备方法及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196195A (en) * 1990-03-27 1993-03-23 Cornell Research Foundation, Inc. Use of arginase to control nitric oxide formation
AU5192498A (en) * 1996-12-03 1998-06-29 Kyowa Hakko Kogyo Co. Ltd. Tissue fibrosis inhibitor
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
WO2002009741A1 (en) * 2000-07-27 2002-02-07 Angiolab, Inc. The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis
WO2004000349A1 (en) 2002-06-20 2003-12-31 Bio-Cancer Treatment International Limited Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
HK1053577A2 (en) 2002-06-20 2003-10-10 Bio-Cancer Treatment International Limited Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
KR101241862B1 (ko) * 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
JP2007537981A (ja) * 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
WO2006125632A2 (en) * 2005-05-24 2006-11-30 Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
PT3778885T (pt) 2008-10-31 2023-05-31 Aerase Inc Composições de arginases humanas modificadas e métodos para o tratamento do cancro
EP2376109B1 (en) * 2008-12-19 2019-01-23 MacroGenics, Inc. Covalent diabodies and uses thereof
CA2756442C (en) * 2009-03-26 2016-03-29 The Hong Kong Polytechnic University Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents
CA2766039A1 (en) * 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods
US9255262B2 (en) * 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
ES2897635T3 (es) 2014-04-29 2022-03-02 Bio Cancer Treat International Ltd Métodos y composiciones para modular el sistema inmunológico con la arginasa I
SG11201609274SA (en) * 2014-05-22 2016-12-29 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
WO2016044656A1 (en) * 2014-09-17 2016-03-24 Ansun Biopharma, Inc. Treatment of infection by human enterovirus d68
ES2909074T3 (es) * 2016-05-06 2022-05-05 Phasebio Pharmaceuticals Inc Proteínas de fusión ELP para liberación controlada y sostenida
WO2020009740A2 (en) * 2018-04-25 2020-01-09 Washington University Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
EP4616911A3 (en) * 2018-05-31 2025-12-24 The Chinese University of Hong Kong Arginase albumin binding domain fusion proteins and methods of use thereof
CA3116736A1 (en) * 2018-10-19 2020-04-23 Aerase, Inc. Arginine depletion therapy for treatment of gamt deficiency

Similar Documents

Publication Publication Date Title
JP7576262B2 (ja) 癌、肥満、代謝障害及び関連する合併症と併存症のためのアルギニン枯渇剤の組成と応用
JP2021525749A5 (https=)
JP6704358B2 (ja) 代謝障害を治療するための組成物および使用方法
AU2011212885B2 (en) Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations thereof
EA036985B1 (ru) Композиции и способы лечения метаболических расстройств
JP7729842B2 (ja) ｒｈＦＧＦ２１融合タンパク質、ｒｈＦＧＦ２１融合タンパク質をコードするポリヌクレオチド、ｒｈＦＧＦ２１融合タンパク質を含有する組成物、及びｒｈＦＧＦ２１融合タンパク質の使用
KR102680776B1 (ko) 고호모시스테인혈증 및 호모시스틴뇨증 환자를 치료하기 위한 인간-효소 매개된 호모시스테인의 고갈
JPWO2019228510A5 (https=)
EP1049487B1 (en) Treatment of acute intermittent porphyria (aip) and other porphyric diseases
RU2826185C2 (ru) Композиция и применение истощающих запасы аргинина средств при раке, ожирении, метаболических нарушениях и связанных с ними осложнениях и сопутствующих заболеваниях
HK40101360A (zh) 用於癌症、肥胖症、代谢紊乱和相关并发症及合并症的精氨酸耗竭剂的组合物和应用
JP2022505689A (ja) 治療的使用のための、遺伝子操作された霊長類シスチン／システイン分解酵素
HK40016122A (en) Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria